Mark A. Kay

49.7k citations
296 papers · 33.4k indexed · 14 hit papers · h-index 98
  • Genetics top 0.01%
    • Virus-based gene therapy research 185
    • RNA Interference and Gene Delivery 103
    • CRISPR and Genetic Engineering 103
    • Viral Infectious Diseases and Gene Expression in Insects 44
    • RNA Research and Splicing 25
  • Hepatology top 0.2%
    • Liver physiology and pathology 23
  • Oncology top 0.5%
    • CAR-T cell therapy research 29
    • Viral gastroenteritis research and epidemiology 29

Mark A. Kay

291 papers receiving 32.4k citations

Hit Papers

Evaluating...128199720262006201650010001.5k

Peers

Mark A. Kay
Comparison fields: 5 of 159
  • Genetics 17.3k
  • Molecular Biology 25.5k
  • Hepatology 2.0k
  • Cancer Research 3.1k
  • Oncology 4.4k
Replace Luigi Naldini with:
Luigi Naldini Italy
Johan H. van Es Netherlands
Nick Barker Singapore
Frank L. Graham Canada
Marc van de Wetering Netherlands
Richard C. Mulligan United States
Jeffrey D. Esko United States
Savio L.C. Woo United States
Guangping Gao United States
Beverly L. Davidson United States
Mark A. Kay relative to Luigi Naldini Italy Luigi Naldini's profile →
Citations per field
00.5×1.5×
Luigi Naldini · 1×
Citations per year

Countries citing papers authored by Mark A. Kay

Since Specialization
Citations

This map shows the geographic impact of Mark A. Kay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Kay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Kay more than expected).

Fields of papers citing papers by Mark A. Kay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Kay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Kay. The network helps show where Mark A. Kay may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark A. Kay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark A. Kay Line = papers co-authored together Mark A. Kay links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20251
3 20242
4 202425
5 202310
6 2020128
7 202018
8 201934
9 201620
10 201527
11 20144
12
In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Virusesbreakdown →
2008537
13 2007164
14 2005140
15 200554
16 199978
17 1996107
18 199587
19 199542
20 1992155

About Mark A. Kay

Mark A. Kay is a scholar working on Genetics, Hepatology and Molecular Biology, having authored 296 papers that have together received 33.4k indexed citations. Recurring topics across this work include Virus-based gene therapy research (185 papers), RNA Interference and Gene Delivery (103 papers), CRISPR and Genetic Engineering (103 papers), Viral Infectious Diseases and Gene Expression in Insects (44 papers), Viral gastroenteritis research and epidemiology (29 papers), CAR-T cell therapy research (29 papers), RNA Research and Splicing (25 papers) and Liver physiology and pathology (23 papers). The work is most often cited by research in Genetics (17.3k citations), Molecular Biology (25.5k citations) and Hepatology (2.0k citations). Mark A. Kay has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Anja Ehrhardt, Dirk Grimm, Theresa A. Storm, Leonard Meuse, Clare E. Thomas, Hiroyuki Nakai, Stephen R. Yant, Luigi Naldini, André Lieber and Joseph C. Glorioso. Their work appears in journals such as Molecular Therapy, Human Gene Therapy, Journal of Virology, Blood and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026